Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627414 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL4533762 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL789747 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL21411569 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890414 | 0.80 | SLC7A5 (0.44) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL1146973 | 0.80 | SLC7A5 (0.44) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL2263477 | 0.80 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890415 | 0.80 | SLC7A5 (0.44) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL15962510 | 0.80 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890552 | 0.80 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| CN-115710820-A | Water-repellent and oil-repellent finishing agent and preparation method thereof | 苏州联胜化学有限公司 | 2023-02-24 | — | — | CN | claimed |
| US-20220211899-A1 | PEPTIDE EXHIBITING EXCELLENT ADHESION TO RESINS AND BIOCOMPATIBLE FUNCTIONAL MATERIAL USING SAME | HITACHI, LTD. (JP) | 2022-07-07 | — | — | US | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| EP-3954698-A1 | PEPTIDE EXHIBITING EXCELLENT ADHESION TO RESINS AND BIOCOMPATIBLE FUNCTIONAL MATERIAL USING SAME | Hitachi, Ltd. (JP) | 2022-02-16 | — | — | EP | claimed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | claimed |
| EP-2827883-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-08 | — | — | EP | claimed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | claimed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | claimed |
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | claimed |
| EP-2547355-A2 | TFPI INHIBITORS AND METHODS OF USE | Baxter International Inc. (US) | 2013-01-23 | — | — | EP | claimed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | claimed |
| WO-2011115712-A2 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC (US) | 2011-09-22 | — | — | WO | claimed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-1084137-A1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2001-03-21 | — | — | EP | claimed |
| WO-1999064442-A1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 1999-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | PTGS1 1204/4885SLC7A11 3554/4885SLC1A1 3860/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | PTGS1 1153/4885SLC7A11 3386/4885SLC1A1 3615/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | PTGS1 605/4885SLC7A11 1010/4885SLC1A1 3131/4885 |
| US-10800816-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F13B | PTGS1 1153/4885SLC7A11 3386/4885SLC1A1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.